ReviewNature reviews. Drug discovery2007
The way forward in HCV treatment--finding the right path.
Review in Nature reviews. Drug discovery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.Medicine · 2016Pooled it
- Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Antimicrobial agents and chemotherapy · 2013Trial
- Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Antimicrobial agents and chemotherapy · 2012Trial
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature · 2010Trial
- On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.World journal of gastroenterology · 2010Trial
- Accelerating antiviral drug discovery: lessons from COVID-19.Nature reviews. Drug discovery · 2023Review
- Alkaloid and benzopyran compounds of Melicope latifolia fruit exhibit anti-hepatitis C virus activities.BMC complementary medicine and therapies · 2021Article
- The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands.International journal of environmental research and public health · 2020Article
- Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.Journal of medicinal chemistry · 2019Article
- Investigation of the Immunomodulatory effect of Berberis vulgaris on core-pulsed dendritic cell vaccine.BMC complementary and alternative medicine · 2016Article
- Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.The Journal of general virology · 2016Article
- Drug Pricing Evolution in Hepatitis C.PloS one · 2016Article
- Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.Current gastroenterology reports · 2015Review
- LC-ESI-MS/MS analysis and pharmacokinetics of GP205, an innovative potent macrocyclic inhibitor of hepatitis C virus NS3/4A protease in rats.Molecules (Basel, Switzerland) · 2015Article
- CD81 and hepatitis C virus (HCV) infection.Viruses · 2014Review
- Chutes and ladders in hepatitis C nucleoside drug development.Antiviral research · 2014Review
- Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).The protein journal · 2014Article
- Scotomas in molecular virology and epidemiology of hepatitis C virus.World journal of gastroenterology · 2013Review
- Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.PLoS pathogens · 2013Article
- Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.Antimicrobial agents and chemotherapy · 2013Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet available. Since the identification of HCV as the causative agent of non-A, non-B hepatitis, treatment has progressed rapidly, but morbidity and mortality rates are still predicted to rise. Novel, more efficacious and tolerable therapies are urgently needed, and a greater understanding of the viral life cycle has led to an increase in the number of possible targets for antiviral intervention. Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents.
Indexed as
Identifiers
18049473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.